Klin Farmakol Farm. 2017;31(3):35-37 | DOI: 10.36290/far.2017.019

Odefsey and its current role in treating HIV infection

David Jilich
Klinika infekčních, tropických a parazitárních nemocí, Nemocnice Na Bulovce a 1. LF UK v Praze

Antiretroviral treatment is the only generally accepted method for treating HIV infection. Given the need for long-term andeveryday use of antiretroviral drugs, it is important to use not only highly effective, but also safe and well tolerated medicinalproducts. Recently, major emphasis has been placed on patient comfort in long-term treatment. Single-tablet regimens are atthe cutting edge in this regard, with one of them being Odefsey.

Keywords: Odefsey, HIV, antiretroviral drugs, NNRTI, rilpivirine, TAF

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jilich D. Odefsey and its current role in treating HIV infection. Klin Farmakol Farm. 2017;31(3):35-37. doi: 10.36290/far.2017.019.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. SPC Odefsey. http://www.sukl.cz/modules/medication/detail.php?code=0209397&tab=texts
    2. http://www.fdanews.com/articles/175612-fda-gives-thumbs-up-to-gileads-odefsey
    3. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004156/smops/Positive/human_smop_000972.jsp&mid=WC0b01ac058001d127
    4. European AIDS Clinical Society (EACS). European Guidelines for treatment of HIV-positive adults in Europe, version 8.0, 2015. http://www.eacsociety.org/files/guidelines_9.0-english-revised_20171025.pdf
    5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infectedadults and adolescents. http://www.aidsinfo.nih.gov
    6. Doporučený postup péče o dospělé infikované HIV a postexpoziční profylaxe infekce HIV. http://infekce.cz/DoporART16.htm
    7. Hoffmann Ch, Rockstroh J. HIV Book 2015/2016. www.hivbook.com
    8. Palella F, Tebas P, Gazzard B, et al. SPIRIT study: switching to emtricitabine/rilpivirine/tenofovir df single-tablet regimen from ritonavir-boosted protease inhibitor and two nukleoside reverse transcriptase inhibitors maintains HIV supression. Abstract TUAB0104, XIX WAC 2012, Washington
    9. DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Martorell CT, de Wet J, Stellbrink HJ, Molina JM, Post FA, Valero IP, Porter D, Liu Y, Cheng A, Quirk E, SenGupta D, Cao H. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017; 4(5): e205-e213. Go to original source... Go to PubMed...
    10. Orkin C, DeJesus E, Ramgopal M, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV 2017; published online Mar 1. http://dx.doi.org/10.1016/S2352-3018(17)30031-0. Go to original source...
    11. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-246. Go to original source...
    12. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229-237. Go to original source...
    13. www.hiv-druginteractions.org

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.